Associated Papers
The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation.
Picard N et al.
Expert Opinion on Drug Metabolism & Toxicology, 2011
UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients.
van Schaik RH et al.
Clinical Pharmacology and Therapeutics, 2009
Analysis of inherited genetic variations at the UGT1 locus in the French-Canadian population.
Ménard V et al.
Human Mutation, 2009
The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers.
Lévesque E et al.
Clinical Pharmacology and Therapeutics, 2007
Genetic variability, haplotypes, and htSNPs for exons 1 at the human UGT1A locus.
Thomas SS et al.
Human Mutation, 2006
Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone.
Thibaudeau J et al.
Cancer Research, 2006
Select a paper to view details